AP2S1 regulates APP degradation through late endosome–lysosome fusion in cells and APP / PS1 mice
Traffic · 2023-01 · 24 (1) · 20-33
DOI: 10.1111/tra.12874 ↗At a glance
Journal article in Traffic, published online on 2022-12-13. Written by Qi-Xin Wen and 11 co-authors. Institution: Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Major Neurological and Mental Dis…. Major MEDLINE topics: Alzheimer Disease, Adaptor Protein Complex sigma Subunits. Cited 19 times so far (Crossref); 99 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China.
Abstract (original language)
AP2S1 is the sigma 2 subunit of adaptor protein 2 (AP2) that is essential for endocytosis. In this study, we investigated the potential role of AP2S1 in intracellular processing of amyloid precursor protein (APP), which contributes to the pathogenesis of Alzheimer disease (AD) by generating the toxic β‐amyloid peptide (Aβ). We found that knockdown or overexpression of AP2S1 decreased or increased the protein levels of APP and Aβ in cells stably expressing human full‐length APP695, respectively. This effect was unrelated to endocytosis but involved lysosomal degradation. Morphological studies revealed that silencing of AP2S1 promoted the translocalization of APP from RAB9‐positive late endosomes (LE) to LAMP1‐positive lysosomes, which was paralleled by the enhanced LE‐lysosome fusion. In support, silencing of vacuolar protein sorting‐associated protein 41 (VPS41) that is implicated in LE‐lyso fusion prevented AP2S1‐mediated regulation of APP degradation and translocalization. In APP/PS1 mice, an animal model of AD, AAV‐mediated delivery of AP2S1 shRNA in the hippocampus significantly reduced the protein levels of APP and Aβ, with the concomitant APP translocalization, LE‐lyso fusion and the improved cognitive functions. Taken together, these data uncover a LE‐lyso fusion mechanism in APP degradation and suggest a novel role for AP2S1 in the pathophysiology of AD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Major Neurological and Mental Disorders, Chongqing Key Laboratory of Neurology, Chongqing, China.
- Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Institute for Brain Science and Disease, Chongqing Medical University, Chongqing, China.
ORCID profiles: Qi-Xin Wen
Funding
- National Natural Science Foundation of China
Cite
APA
Wen, Q. X., Luo, B., Xie, X. Y., Zhou, G. F., Chen, J., Song, L., Liu, Y., Xie, S. Q., Chen, L., Li, K. Y., Xiang, X. J., & Chen, G. J. (2023). AP2S1 regulates APP degradation through late endosome–lysosome fusion in cells and APP / PS1 mice. Traffic, 24(1), 20-33. https://doi.org/10.1111/tra.12874
Vancouver
Wen QX, Luo B, Xie XY, Zhou GF, Chen J, Song L, et al. AP2S1 regulates APP degradation through late endosome–lysosome fusion in cells and APP / PS1 mice. Traffic. 2023;24(1):20-33. doi:10.1111/tra.12874
BibTeX
@article{Wen2023,
author = {Wen, Qi-Xin and Luo, Biao and Xie, Xiao-Yong and Zhou, Gui-Feng and Chen, Jian and Song, Li and Liu, Yue and Xie, Shi-Qi and Chen, Long and Li, Kun-Yi and Xiang, Xiao-Jiao and Chen, Guo-Jun},
title = {AP2S1 regulates APP degradation through late endosome–lysosome fusion in cells and APP / PS1 mice},
journal = {Traffic},
year = {2023},
volume = {24},
number = {1},
pages = {20--33},
doi = {10.1111/tra.12874}
}
EUVIMED